Marksans Pharma’s manufacturing facility at Verna, Goa approved by Australian TG

The products will be manufactured in Goa India and marketed & distributed in Australian markets

Marksans Pharma Q1 FY25 revenue up 18%

Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%

Marksans Pharma updates on USFDA inspection at Verna, Goa manufacturing facility

Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr

US business grew by +12.8% YoY

Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals

Marksans Pharma completes acquisition of manufacturing site from Tevapharm India

Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards

Marksans Pharma announces USFDA approval for Famotidine Tablets

Marksans' OTC Famotidine Tablets USP are acid reducers

Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK

Marksans Pharma raises Rs. 372.40 crores

OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.

Marksans Pharma posts Q1FY23consolidated PAT at Rs. 59.71 Cr

The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.